Cargando…

PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation

The relevance of PCSK9 in atherosclerosis progression is demonstrated by the benefits observed in patients that have followed PCSK9-targeted therapies. The impact of these therapies is attributed to the plasma lipid-lowering effect induced when LDLR hepatic expression levels are recovered after the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Luquero, Aureli, Badimon, Lina, Borrell-Pages, Maria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8021767/ https://www.ncbi.nlm.nih.gov/pubmed/33834043 http://dx.doi.org/10.3389/fcvm.2021.639727

Ejemplares similares

PCSK9/LDLR System and Rheumatoid Arthritis-Related Atherosclerosis
por: Arida, Aikaterini, et al.
Publicado: (2021)

Microvesicles carrying LRP5 induce macrophage polarization to an anti‐inflammatory phenotype
por: Luquero, Aureli, et al.
Publicado: (2021)

The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol
por: Seidah, Nabil G.
Publicado: (2017)

Regulation of PCSK9 Expression and Function: Mechanisms and Therapeutic Implications
por: Xia, Xiao-dan, et al.
Publicado: (2021)

Role of PCSK9 in Homocysteine-Accelerated Lipid Accumulation in Macrophages and Atherosclerosis in ApoE(−/−) Mice
por: Jin, Ping, et al.
Publicado: (2021)

Proteomics and Lipidomics to unveil the contribution of PCSK9 beyond cholesterol lowering: a narrative review
por: Gianazza, Erica, et al.
Publicado: (2023)

Investigating the lowest threshold of vascular benefits from LDL cholesterol lowering with a PCSK9 mAb inhibitor (alirocumab) in healthy volunteers – a mechanistic physiological study (INTENSITY-LOW): protocol and study rationale
por: Kostapanos, Michael S., et al.
Publicado: (2019)

Associations Among PCSK9 Levels, Atherosclerosis-Derived Extracellular Vesicles, and Their miRNA Content in Adults With Obesity
por: Macchi, Chiara, et al.
Publicado: (2022)

Glycation of LDL: AGEs, impact on lipoprotein function, and involvement in atherosclerosis
por: Poznyak, Anastasia V., et al.
Publicado: (2023)

PCSK9 inhibitors for anti-inflammation in atherosclerosis: protocol for a systematic review and meta-analysis of randomised controlled trials
por: Luo, Jichang, et al.
Publicado: (2022)

Physical activity to reduce PCSK9 levels
por: Tirandi, Amedeo, et al.
Publicado: (2022)

LDL‐cholesterol and PCSK9 in patients with familial hypercholesterolemia: influence of PCSK9 variants under lipid‐lowering therapy
por: Hamasaki, Masato, et al.
Publicado: (2021)

Microvesicles in Atherosclerosis and Angiogenesis: From Bench to Bedside and Reverse
por: Badimon, Lina, et al.
Publicado: (2017)

Effect of PCSK9 on atherosclerotic cardiovascular diseases and its mechanisms: Focus on immune regulation
por: Ma, Minglu, et al.
Publicado: (2023)

Investigating the Lowest Threshold of Vascular Benefits from LDL Cholesterol Lowering with a PCSK9 mAb Inhibitor (Alirocumab) in Patients with Stable Cardiovascular Disease (INTENSITY-HIGH): protocol and study rationale for a randomised, open label, parallel group, mechanistic study
por: Cacciottolo, Paul J, et al.
Publicado: (2021)

Mechanisms of Oxidized LDL-Mediated Endothelial Dysfunction and Its Consequences for the Development of Atherosclerosis
por: Jiang, Hui, et al.
Publicado: (2022)

PCSK9 inhibitors for acute coronary syndrome: the era of early implementation
por: Chen, Hongzhen, et al.
Publicado: (2023)

Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9
por: Schmidt, Amand F., et al.
Publicado: (2019)

In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels
por: Rothgangl, Tanja, et al.
Publicado: (2021)

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
por: Schwartz, Gregory G., et al.
Publicado: (2021)

Prevalence and Impact of Apolipoprotein E7 on LDL Cholesterol Among Patients With Familial Hypercholesterolemia
por: Tada, Hayato, et al.
Publicado: (2021)

Efficacy and safety of PCSK9 monoclonal antibodies: an evidence-based review and update
por: Kaddoura, Rasha, et al.
Publicado: (2020)

Macrophages of genetically characterized familial hypercholesterolaemia patients show up‐regulation of LDL‐receptor‐related proteins
por: Escate, Rafael, et al.
Publicado: (2016)

Legacy perfluoro-alkyl substances impair LDL-cholesterol uptake independently from PCSK9-function
por: Sabovic, Iva, et al.
Publicado: (2023)

Interpreting the Findings From the Recent PCSK9 Monoclonal Antibody Cardiovascular Outcomes Trials
por: Wong, Nathan D., et al.
Publicado: (2019)

Independent association of PCSK9 with platelet reactivity in subjects without statin or antiplatelet agents
por: Wang, Shuai, et al.
Publicado: (2022)

Advanced progress of the relationship between PCSK9 monoclonal antibodies and hyperglycemic adverse events
por: Zhang, Ruixing, et al.
Publicado: (2023)

High-Throughput Screening Identifies MicroRNAs Regulating Human PCSK9 and Hepatic Low-Density Lipoprotein Receptor Expression
por: van Solingen, Coen, et al.
Publicado: (2021)

An Anti-PCSK9 Antibody Reduces LDL-Cholesterol On Top Of A Statin And Suppresses Hepatocyte SREBP-Regulated Genes
por: Zhang, Liwen, et al.
Publicado: (2012)

Hematopoietic Cell-Specific SLC37A2 Deficiency Accelerates Atherosclerosis in LDL Receptor-Deficient Mice
por: Zhao, Qingxia, et al.
Publicado: (2021)

Bayesian network analysis of panomic biological big data identifies the importance of triglyceride-rich LDL in atherosclerosis development
por: Voros, Szilard, et al.
Publicado: (2023)

Cardiovascular Outcomes of PCSK9 Inhibitors: With Special Emphasis on Its Effect beyond LDL-Cholesterol Lowering
por: Bandyopadhyay, Dhrubajyoti, et al.
Publicado: (2018)

Small, Dense Low-Density Lipoprotein-Cholesterol and Atherosclerosis: Relationship and Therapeutic Strategies
por: Jin, Xiao, et al.
Publicado: (2022)

Endothelial ADAM10 controls cellular response to oxLDL and its deficiency exacerbates atherosclerosis with intraplaque hemorrhage and neovascularization in mice
por: van der Vorst, Emiel P. C., et al.
Publicado: (2023)

Case report: Coronary atherosclerosis in a patient with long-standing very low LDL-C without lipid-lowering therapy
por: Mottola, Giorgio, et al.
Publicado: (2023)

Discordance of Apolipoprotein B, Non-HDL-Cholesterol, and LDL-Cholesterol Predicts Risk of Increased Arterial Stiffness and Elevated Carotid Intima-Media Thickness in Middle-Aged and Elderly Chinese Adults
por: Jia, Xiaojing, et al.
Publicado: (2022)

Comparison of Low-Density Lipoprotein Cholesterol (LDL-C) Goal Achievement and Lipid-Lowering Therapy in the Patients With Coronary Artery Disease With Different Renal Functions
por: Zhang, Shuang, et al.
Publicado: (2022)

PCSK9 inhibitors in a renal transplant patient complicated with hepatitis B: A case report and literature review
por: Lv, Pinchao, et al.
Publicado: (2022)

PCSK9 and Atherosclerosis - Lipids and Beyond
por: Shapiro, Michael D., et al.
Publicado: (2017)

An Update on the Role of PCSK9 in Atherosclerosis
por: Yurtseven, Ece, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4c7gm4csipb1n4i3v9aeth1hie